Advertisement
Screener

NEUMORA THERAPEUTICS, INC. (NMRA) Income Taxes Paid

NEUMORA THERAPEUTICS, INC. Income Taxes Paid

NEUMORA THERAPEUTICS, INC. (NMRA) reported Income Taxes Paid of $30.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Other Cash Flow Items

us-gaap:IncomeTaxesPaidNet · last filed 2026-08-14

  • NEUMORA THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2026-06-30 was $0.00.
  • NEUMORA THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2026-03-31 was $30.00K.
  • NEUMORA THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2025-12-31 was $323.00K.
  • NEUMORA THERAPEUTICS, INC. income taxes paid, net for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
  • NEUMORA THERAPEUTICS, INC. income taxes paid, net for fiscal 2025 was $323.00K, a 31.71% decline from fiscal 2024.
  • NEUMORA THERAPEUTICS, INC. income taxes paid, net for fiscal 2024 was $473.00K.
Period endIncome Taxes Paid, Net 3 monthIncome Taxes Paid, Net 6 monthIncome Taxes Paid, Net 6 month as first filedIncome Taxes Paid, Net 9 monthIncome Taxes Paid, Net 12 month
2026-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
$30.00K
10-Q · filed 2026-08-14
$353.00K
derived: sum of 3 quarters · filed 2026-08-14
$353.00K
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$30.00K
10-Q · filed 2026-05-07
$353.00K
derived: sum of 2 quarters · filed 2026-05-07
$353.00K
derived: sum of 3 quarters · filed 2026-05-07
$353.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$323.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$323.00K
derived: sum of 2 quarters · filed 2026-03-30
$323.00K
derived: sum of 3 quarters · filed 2026-08-14
$323.00K
10-K · filed 2026-03-30
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$0.00
derived: sum of 2 quarters · filed 2026-08-14
$0.00
10-Q · filed 2025-11-06
$0.00
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
$0.00
10-Q · filed 2026-08-14
$134.00K
10-Q · filed 2025-08-06
$0.00
derived: sum of 3 quarters · filed 2026-08-14
$473.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$0.00
10-Q · filed 2026-05-07
$0.00
derived: sum of 2 quarters · filed 2026-05-07
$473.00K
derived: sum of 3 quarters · filed 2026-05-07
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$473.00K
derived: sum of 2 quarters · filed 2026-03-30
$473.00K
10-K · filed 2026-03-30
2024-09-30$473.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$473.00K
10-Q · filed 2025-11-06
2024-06-30$0.00
10-Q · filed 2025-08-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22